Boeing’s Path Forward: Manufacturing and Regulatory Hurdles Define the Journey

Boeing is working to move beyond its recent crises. The narrative is shifting from addressing past failures to a present defined by two critical challenges: reliably certifying its aircraft and ramping up delivery rates. Consequently, the performance of Boeing’s stock is now intrinsically linked to the efficiency of its factories and the pace at which regulators grant approvals for new models.

Production Momentum Offers a Glimmer of Hope

Operationally, manufacturing performance has taken center stage. With inventories of completed but undelivered jets reduced, future delivery growth is directly tied to increasing production rates. The company demonstrated tangible progress in 2025, closing the year with its highest number of commercial airplane deliveries since 2018.

For the full year 2025, Boeing handed over 600 commercial jets—a significant increase over prior years. This surge was primarily driven by the 737 MAX program. In the fourth quarter alone, 117 MAX aircraft were delivered, accounting for the bulk of single-aisle volumes. During the same period, the long-range 787 Dreamliner program saw 27 aircraft reach customers.

The market is now closely watching to see if this represents a sustainable trend or merely a temporary peak. Each monthly delivery report serves as a test of Boeing’s ability to reliably hit production targets, thereby laying the groundwork for improved free cash flow and addressing its still-strained balance sheet.

Providing context for investor sentiment, the share price has recovered markedly over the past twelve months, gaining approximately 47%. It currently trades at a new 52-week high of $251.41, standing about 33% above its 200-day moving average. This valuation reflects substantial market expectation for a continuation of the operational recovery.

A Grueling Certification Process

Regulatory pressure remains intense. The U.S. Federal Aviation Administration (FAA) has made it clear that Boeing bears full responsibility for securing the pending certifications for the 737 MAX 7 and MAX 10 variants. Current estimates suggest the MAX 7 could receive its type certification by mid-2026, with the MAX 10 likely to follow no earlier than late 2026.

Should investors sell immediately? Or is it worth buying Boeing?

These timelines represent a central uncertainty. Without certification, airlines cannot integrate the new models into their fleets, disrupting order and delivery schedules. For Boeing, this delays the opportunity to fully position its model lineup in the market and achieve higher volumes in the lucrative single-aisle segment.

Further pressure comes from another delay in the long-haul sector. The 777X program has been pushed back again, with first deliveries now scheduled for 2027. The postponement of this key widebody jet complicates efforts to supply customers with more efficient aircraft in a timely manner and pushes potential revenue contributions further into the future.

Defense Segment Provides a Steadying Counterbalance

While the commercial division grapples with certification requirements and schedule shifts, the defense business offers a crucial stabilizing force. In late December 2025, Boeing announced two major U.S. Department of Defense contracts: an $8.6 billion order for F-15IA fighter jets for the Israeli Air Force and a $4.2 billion logistics contract for the U.S. Air Force.

These agreements provide long-term, predictable revenue streams and help cushion the impact of potential setbacks in commercial airplane manufacturing. In 2025, the defense and space division delivered a total of 131 aircraft, underscoring its role as a stabilizing earnings pillar.

The Road Ahead: A Delicate Balance

The coming quarters present a clearly defined scenario. On one side are firm defense contracts and rising commercial airplane deliveries. On the other is a tight regulatory environment and delayed programs like the 737 MAX 7, MAX 10, and 777X. The crucial test will be whether Boeing can sustain the production ramp-up of the 737 MAX and 787 without new quality issues while simultaneously meeting promised certification deadlines.

If the company successfully combines operational discipline with predictable regulatory approvals, the strong 2025 delivery figures could mark the starting point for further improvements in cash flow and balance sheet health. However, any setbacks in certification or manufacturing would not only impact the operational profile but could also correct a share price that already incorporates a significant degree of optimism.